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A B S T R A C T 
Purpose: This article reflects the report by the British Branch of the International League Against 
Epilepsy (ILAE) Working Group on services for adults with epilepsy and intellectual disability (ID). Its 
terms of reference was to explore the current status of aspects of the care of people with an ID and 
epilepsy. Methods: Survey content was developed from key themes identified by consensus of the 
working group. An electronic survey was distributed via email. The sample population was the 
membership of the ILAE UK, Royal College of Psychiatrists (RCPsych) Faculty of ID, Epilepsy Nurses 
Association (ESNA), and the Association of British Neurologists (ABN). Following a six week 
response period the data was then collated, anonymised and distributed to the working group in order 
that opinion statements could be gathered. Results: The time taken for individuals with both new-
onset and established epilepsy to undergo routine investigation was commonly at least 1–3 months, 
far beyond recommendations made by NICE (CG20). A small minority of clinicians would not consider 
non-pharmacological interventions including epilepsy surgery, vagus nerve stimulation, and ketogenic 
diet for this population. Almost universally responders are actively involved in the assessment and 
management of key risk areas including risk of drowning, hospitalization, medication side effects, and 
sudden unexpected death in epilepsy (SUDEP). Conclusion: This investigation identifies key themes 
and recommendations relating to care delivery and meeting the complex needs of people with ID and 
epilepsy. Adults with ID and epilepsy appear to exist in a unique, but inadequate, segment of epilepsy 
care delivery. 
 
1. Introduction 
“It is not always clear who should be responsible for care of these patients and their epilepsy. In some 
areas learning disability services offer epilepsy management, this may be in place of or in addition to 
neurological services.” (respondent). “The care this population receive appears fragmented and 
inadequate.” (respondent). This article reflects the report by the British Branch of the International 
League Against Epilepsy (ILAE) Working Group on services for adults with epilepsy and intellectual 
disability. Its terms of reference was to explore the current status of aspects of the care of people with 
an intellectual disability and epilepsy as a response to the White Paper; a special report on the 
medical and social needs of people with epilepsy and intellectual disability by the task force on 
intellectual disabilities and epilepsy of the ILAE [1]. The White paper highlights key areas of concern 
where action is needed to improve the care provided for people with intellectual disability and epilepsy 
developed using the views of patient groups and carer organizations. 
 
Areas of concern in the care of people with epilepsy and intellectual disability:   
Diagnosis and medical treatment   
Service delivery 
Education and employment  
Social, romantic, and family life 
 
1.1. Epilepsy and intellectual disability  
There is a strong positive correlation between epilepsy and intellectual disability (ID). Both may be 
caused by a wide range of pathological insults during neurodevelopment. The prevalence of epilepsy 
increases with the severity of ID [2], and people with epilepsy and ID often experience multiple 
seizure types that are resistant to drug treatment [3]. People with ID and active epilepsy are also at 
greater risk of mental illness compared to the general population [4]. There are consensus guidelines 
for the management of behavioural mani-festations and neuropsychiatric disturbance [5,6]. Good 
manage-ment of epilepsy in this population is particularly important as there is increased risk of 
sudden unexplained death in epilepsy (SUDEP) [7]. An evidence based risk factor checklist is 
available to guide person-centred discussion around risk [8]. The presence of other physical, 
psychological, and neuro-developmental co-morbidities may alter the approach to assess-ment and 
diminish the reliability of generic assessment tools and accuracy of information. People with epilepsy 
and ID often have a wide range of complex needs – but undergo less diagnostic investigations and 
have less contact with specialist epilepsy services [9]. The health inequalities experienced by the ID 
population have been well established [10], and part of the reason for poorer health outcomes is 
related to problems with diagnosis and medical management [10,11]. Reasonable adjustments should 
be in place to ensure equitable access to specialist health care and prevent fragmentation of care. 
This is of particular importance to people with ID who may lack the capacity to make decisions. 
2. Methods  
The British Branch of the International League Against Epilepsy (ILAE) Working Group on services for 
adults with ID and epilepsy was assembled inviting representatives from key stakeholders including 
ILAE (MPK), Royal College of Psychiatrists ID Faculty (AR, RS, LVW), Association of British 
Neurologists (HAL), Epilepsy Nurses Association (AC, CH, MG). Patient/carer based organisations 
were the source of information provided in the White Paper, and were thus not included again in the 
current working group. The survey content was developed from themes identified by consensus of the 
working group following consecutive rounds of discussion. These themes were developed from the 
key areas of concern identified in the White paper and include additional aspects of epilepsy care 
relevant to professionals. The survey included a mixture of quantitative questions and free text for 
qualitative data in order to ensure main aspects of enquiry were covered and that respondents had 
space to provide a narrative. The data was collected via an online survey. The electronic survey was 
distributed via email with support from the ILAE to the target audience, including a wide range of 
health professionals involved in delivering care to people with ID and epilepsy. The sample population 
was the membership of the ILAE UK (800 total members approximately), Royal College of 
Psychiatrists (RCPsych) Faculty of ID (2361), Epilepsy Nurses Association (ESNA) (340), and the 
Association of British Neurologists (ABN) (756). A six week response period was allocated. The 
respondents’ data was then collated, anonymised, and distributed to the working group in order that 
opinion statements could be gathered. Key themes identified by working group:  
Diagnosis and medical treatment   
Delivery of service   
Risk  
Broader impact upon quality of life 
 
3. Results 
The results of this survey and subsequent recommendations arise from the opinions of professionals 
involved in the care of people with epilepsy and ID. The results do not draw comparisons of service 
provision or their relative efficacy. The survey was completed by a total of 54 respondents. The 
professions of those completing the survey were Psychiatrists in ID (20), Epilepsy Specialist Nurse 
(15), Neurologist (12), Learning Disability Nurse (2), and other (5). Responses were received from a 
wide range of geographical locations across the United Kingdom, and also included a small number of 
international responses.  
The professionals involved in delivering care to people with ID and epilepsy work in a variety of 
settings. Almost half (46%) review patients at a District General Hospital (DGH), 44% work within 
Learning Disability services, 37% work in community clinics, 32% use community domiciliary visits, 
and 26% review patients at a tertiary epilepsy centre. The percentage of workload spent treating 
epilepsy by these professionals ranged between 9% and 30%. The percentage of case load with a 
diagnosis of ID showed two distinct peaks at 10–30% and 70–100%. The main body of results are 
presented as per the key domains identified by the working group at the outset.  
 
3.1. Diagnosis, medical treatment and the delivery of service  
 
3.1.1. New onset epilepsy  
The time taken for patients with ID and new onset epilepsy to undergo MRI brain scan varied between 
0-2 weeks (9%), 2–4 weeks (19%), 1–3 months (39%), 3–6 months (9%), none wait longer than 6 
months, with 28% of responders having to refer through other clinicians to request the investigation. 
The length of time for MRI under general anaesthetic (GA) was 0–2 weeks (4%), 2–4 weeks (4%), 1–
3 months (24%), 3–6 months (20%), more than 6 months (15%), with 39% of clinicians unable to 
request such investigations and needing to refer to other departments. The usual waiting time for a 
standard Electroencephalogram (EEG) was 0–2 weeks (6%), 2–4 weeks (33%),1–3 months (39%), 
3–6 (20%), more than 6 months (15%), with 39% of clinicians unable to request such investigations 
and needing to refer to other departments.  
The usual waiting time for a standard Electroencephalogram (EEG) was 0–2 weeks (6%), 2–4 weeks 
(33%),1–3 months (39%), 3–6 months (0%), more than 6 months (2%), with 22% of clinicians unable 
to request this investigation and needing to refer to other departments.   
 
3.1.2. Established epilepsy and ongoing management 
The expected waiting time for a Computerised Tomography (CT) scan in this population was 0–2 
weeks (11%), 2–4 weeks (32%), 1–3 months (31.5%), 3–6 months (2%), more than 6 months (0%), 
26% are unable to request such investigation are required to refer through other clinicians. The 
expected waiting time for MRI is 0–2 weeks (4%), 2–4 weeks (15%), 1–3 months (44%), 3–6 months 
(6%), more than 6 months (2%), 28% are unable to request such investigation are required to refer 
through other clinicians. The expected waiting time for MRI under GA was 0–2 weeks (2%), 2–4 
weeks (6%), 1–3 months (20%), 3–6 months (22%), more than 6 months (13%), with 37% unable to 
request such investigation are required to refer through other clinicians.  
 
3.1.3. Rescue medication  
Almost four in five (80%) of clinicians surveyed are involved in the prescription of Midazolam (buccal), 
48% Diazepam (rectal), 22% Paraldehyde (rectal), 41% Lorazepam (tablets), and 32% other. The 
majority of respondents play an active role in the implementation and management of rescue 
medication protocols. This includes devising rescue medication protocols (76%), renew- ing rescue 
medication protocols (76%), providing education/ training to other professionals around rescue 
medication (41%), and providing education/training to families or care providers around rescue 
medication (56%). 
 
3.1.4. Non pharmacological interventions 3.1.4.1. Epilepsy surgery. The majority (78%) of responders 
have access to and would consider epilepsy surgery for people with ID and epilepsy. A small 
percentage (6%) has access to epilepsy surgery but would not consider it for this population group. 
Less than 1 in 6 (15%) of responders do not have epilepsy surgery available but would consider it if 
available, and 2% would not consider it even if it was an available option. Those professionals who do 
not consider epilepsy surgery consist of general practitioners (GPs) with a special interest in epilepsy 
and learning disability nurses. 3.1.4.2. Vagus nerve stimulation (VNS). Nearly all responders (85%) 
have VNS available and would consider it for people with ID and epilepsy. A small number (7%) of 
responders do not have access to VNS but would consider it if they did. A minority of responders (6%) 
who have access to VNS would not consider it for this patient group, and 2% do not have access to 
VNS and would not considers it in any case. 3.1.4.3. Ketogenic diet. Less than one third (31%) of 
responders have access to implementation of a ketogenic diet and consider it as a management 
strategy. Less than one in five (19%) have access to a ketogenic diet service but do not consider it. 
About one-third of responders (35%) do not have access to the ketogenic diet but would consider it, 
the remainder (15%) do not have access and would not consider the use of a ketogenic diet. Included 
in respondents who would not consider ketogenic diet are specialists of different professions working 
in tertiary epilepsy centres. 
3.1.4.4. Deep brain stimulation. Only a minority of clinicians involved in this survey (11%) have access 
to deep brain stimulation and would consider it for this population. A similar proportion (13%) of 
clinicians who have access to deep brain stimulation would not consider it. The majority of 
respondents do not have access to deep brain stimulation, of this group the half would not consider it, 
but 30% would if it were available.  
 
3.2. Risk  
Epilepsy is associated with a wide range of risks. The National Institute for Health and Care 
Excellence (NICE) 137 guidelines state that all individuals and their families should be provided with, 
and have access to, information around risk management [12]. Respondents were asked to consider 
a number of common risks associated with epilepsy in people with an ID and whether they are 
actively involved in assessing and managing these risks. Nearly nine of every ten (87%) responders 
are actively involved in the assessment and management of sudden unexplained death in epilepsy 
(SUDEP), risk of drowning (83%), hospitalization (69%), side effects of medication (94%), 
observational devices and sensors (48%). 3.3. Broader impact on quality of life Epilepsy impacts on 
all aspects of an individual and can have significant effects on quality of life. It is particularly important 
for people with ID and epilepsy that clinicians consider this broader impact as this population may 
already have significant restriction upon their ability to live independently. Responders were asked to 
consider particular areas that a diagnosis of epilepsy may impact upon. The majority of responders 
are involved in addressing these core area including education (61%), employment (59%), social 
factors (83%), and family support (89%). 3.4. The views of respondents–options and solutions As 
described the respondents provided detailed free text answers within the questionnaire. The total free 
text responses were then transcribed and analysed for themes (MK). Ten themes emerged which 
were agreed by the working group. Table 1 identifies these themes and provides direct quotations 
from respondents. The responses have not been further qualitatively analysed in order to preserve 
examples of the raw data providing ‘real world’ opinions from clinicians working with people with 
epilepsy and ID. This data has been used by the working group to help develop recommendations 
(Table 2). 
 
4. Discussion  
The British Branch of the International League Against Epilepsy (ILAE) Working Group on services for 
adults with ID and epilepsy identified key themes relating to care delivery and meeting complex 
needs. Importantly the findings in this report come from the response of the membership of the ILAE 
and other representative professional bodies in the UK. Adults with ID and epilepsy appear to exist in 
a unique, but inadequate, segment of epilepsy care delivery. This contrasts with paediatric epilepsy, 
mainly specialist driven by paediatric service, or adult epilepsy without ID, residing in adult neurology 
and primary care. Care of adults with an ID in the UK is shared between neurology, ID and primary 
care services. At its best these service can manage individuals with a high level of excellence either 
uniquely within one service or working together. This model provides the skills to meet the needs of 
people identified by the White paper [1]. There is evidence that care delivery is fragmented in some 
areas. This leads to significant disparity and inequality of care across the UK for adults with an ID. 
The British ILAE is working to promote collaboration between the key stakeholders and governing 
bodies involved in the delivery of care to this population. The development of care pathways will help 
ensure that the needs of people with ID and epilepsy are met and reasonable adjustments are made. 
Collaboration between professional groups will allow sharing of expertise to ensure that patients 
receive person centred care. There needs to be a specific focus on the complex needs of this 
population. Delivery of care will require the input of multiple professionals, however, there needs to be 
one recognised responsible team or specialist to co-ordinate care. Following the findings of this report 
the RCPsych ID faculty has proposed a strategy for clinicians to better support their patients with 
epilepsy [13]. A tiered competency model (Bronze/Silver/ Gold) is proposed to evidence 
competencies against the National Institute for Health and Care Excellence (NICE) outcome 
indicators for epilepsy and the Scottish Intercollegiate Guidelines Network (SIGN) guidance [12,14].  
 
 
 
 
 
 
There are many areas for improvement and the Working Group has identified actions (Table 2). 
These offer a blueprint for change that could address the current inequalities in care provision for this 
important group of people with epilepsy. 
Limitations of study  
 
The overall response rate to this survey is low considering the number of potential responders from 
each stakeholder group surveyed. The views considered therefore represent only a small sample of 
the potential professionals involved in the care of people with epilepsy and ID. This raises concerns of 
bias and the views may represent those individuals with a keen interest in the field and not provide a 
true representation of care provision with generalizable results. We also have to consider that not all 
members of the organizations surveyed are currently in clinical practice. This potential bias is 
reflected in the recommendations made by the group which go beyond the findings of the survey 
which are largely positive. 
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